Alphamab Oncology (Stock Code: 9966.HK) announced that the IND application for a Phase II clinical study of JSKN033 (a proprietary high-concentration subcutaneous co-formulation consisting of HER2 ...
A privately held biopharmaceutical company based in the United States. Its development and planned commercialization ...
Exploring clinical development plan options including a controlled human infection model (CHIM) and a Phase 2/3 adaptive ...
Pharmaceutical Technology on MSN
Revamping best-selling drugs to combat patent cliff has limits
Updated versions of best-selling drugs may mitigate some of the impact of patent cliff losses, but the strategy behind the ...
Clinical setbacks, worse-than-expected financial results, and a loss of market share in its most important therapeutic area ...
Barchart on MSN
This Small But Mighty Stock Could Surprise Investors in 2026
Let’s find out if it is a good time to buy the stock before the year ends. Valued at $4.2 billion, Viking Therapeutics is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback